<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01699828</url>
  </required_header>
  <id_info>
    <org_study_id>186/2011</org_study_id>
    <nct_id>NCT01699828</nct_id>
  </id_info>
  <brief_title>Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET</brief_title>
  <official_title>Exploring Occupancy of Dopamine D3 Receptor by Buspirone in Humans Using PET</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the present study is to use positron emission tomography brain imaging to&#xD;
      investigate D3 occupancy of buspirone, an FDA-approved anxiolytic which acts as a serotonin&#xD;
      partial agonist but has recently been identified as a D3 antagonist. It is hypothesized that&#xD;
      clinically relevant doses of buspirone will occupy the D3 receptor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Buspirone is used for anxiety disorder treatment, a therapeutic effect that has been thought&#xD;
      to be mediated through its partial agonist properties at the serotonin receptor. However,&#xD;
      since one PET study in humans has shown low occupancy of the serotonin by buspirone in&#xD;
      clinical doses and since the DRD3 has been recently implicated in anxiety, some therapeutic&#xD;
      effects of buspirone may be mediated through the DRD3. In human clinical studies, promising&#xD;
      effects of buspirone have been reported for treatment of substance dependence, including&#xD;
      tobacco, marijuana, and opiates, and clinical studies in cocaine dependent subjects are&#xD;
      underway. However, it is unclear if buspirone is producing those effects through the DRD3 and&#xD;
      no human study has incorporated a PET imaging component to investigate this question; it&#xD;
      remains unclear whether buspirone significantly occupies the DRD3 at therapeutic doses in&#xD;
      humans.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-response occupancy of buspirone at DRD3</measure>
    <time_frame>few months</time_frame>
    <description>[11C]-(+)-PHNO binding potential at three doses of buspirone and placebo.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Smoking Cessation</condition>
  <condition>Tobacco Use Cessation</condition>
  <arm_group>
    <arm_group_label>Buspirone 120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone 120 mg (encapsulated).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buspirone 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone 60 mg (encapsulated)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (encapsulated)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Buspirone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Buspirone 30 mg (encapsulated).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buspirone</intervention_name>
    <description>The buspirone will be given once as a tablet and encapsulated for blinding.</description>
    <arm_group_label>Buspirone 120 mg</arm_group_label>
    <arm_group_label>Buspirone 30 mg</arm_group_label>
    <arm_group_label>Buspirone 60 mg</arm_group_label>
    <other_name>Buspar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be lactose and encapsulated for blinding. A single capsule will be given.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>lactose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - 19 years or older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical condition including cardiovascular, renal, hepatic or cerebrovascular diseases&#xD;
&#xD;
          -  History of or current neurological illnesses including seizure disorders, migraine,&#xD;
             multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor, - Present or&#xD;
             past psychiatric condition including mood, anxiety, psychotic disorders and substance&#xD;
             abuse and/or dependence.&#xD;
&#xD;
          -  Condition that precludes use of buspirone or that will interfere with participation in&#xD;
             the present study (such as hypersensitive to buspirone hydrochloride).&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Presence of metal objects in the body or implanted electronic devices, that preclude&#xD;
             safe MR scanning.&#xD;
&#xD;
          -  Claustrophobia.&#xD;
&#xD;
          -  Current use or use during the previous month of medication that may affect the CNS,&#xD;
             including monoamine oxidase inhibitor (MAOI) or positive during drug screening for&#xD;
             drugs of abuse or any medication that could increase the risk of buspirone&#xD;
             administration.&#xD;
&#xD;
          -  Exposure to radiation in the last 12 month exceeding permissible limit for subjects&#xD;
             participating in research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Boileau, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Addiction and Mental Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bernard Le Foll, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5S 2S1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.camh.net/research</url>
    <description>Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>October 2, 2012</study_first_submitted>
  <study_first_submitted_qc>October 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2012</study_first_posted>
  <last_update_submitted>June 3, 2014</last_update_submitted>
  <last_update_submitted_qc>June 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Bernard Le Foll</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>buspirone</keyword>
  <keyword>smoking cessation</keyword>
  <keyword>dopamine</keyword>
  <keyword>PET imaging</keyword>
  <keyword>[11C]-(+)-PHNO</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buspirone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

